Gene Silencing News and Research

RSS

U.S. District Court rules in favor of Alnylam in patent infringement case against Tekmira

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that the U.S. District Court of the District of Massachusetts has ruled in favor of Alnylam and has denied Tekmira Pharmaceuticals Corporation's motion to dismiss certain claims and motion to disqualify Alnylam's counsel in an infringement suit filed in January 2012.

26 Sep 2012

LIFR protein suppresses local invasion and metastasis of breast cancer cells

A receptor protein suppresses local invasion and metastasis of breast cancer cells, the most lethal aspect of the disease, according to a research team headed by scientists from The University of Texas MD Anderson Cancer Center.

25 Sep 2012

Small fragments of keratin protein in the eye play a key role in warding off pathogens

When it comes to germ-busting power, the eyes have it, according to a discovery by University of California, Berkeley, researchers that could lead to new, inexpensive antimicrobial drugs.

25 Sep 2012

New light-based technique demonstrates that toxic proteins build up gradually in blood cells

A new light-based technique for measuring levels of the toxic protein that causes Huntington's disease (HD) has been used to demonstrate that the protein builds up gradually in blood cells. Published today (17th) in the Journal of Clinical Investigation, the findings shed light on how the protein causes damage in the brain, and could be useful for monitoring the progression of HD, or testing new drugs aimed at suppressing production of the harmful protein.

18 Sep 2012

Researchers obtain first detailed and complete picture of PRC2 protein

The first detailed and complete picture of a protein complex that is tied to human birth defects as well as the progression of many forms of cancer has been obtained by an international team of researchers led by scientists with the U.S. Department of Energy (DOE)'s Lawrence Berkeley National Laboratory (Berkeley Lab).

18 Sep 2012

Single HPV protein is required for cervical cancer growths to survive

Human papillomavirus (HPV) has long been implicated in cervical cancer, but details of how it happens have remained a mystery. Now researchers at the University of Wisconsin-Madison have found that a single HPV protein is required for cervical cancer and even pre-cancer growths in the cervix to survive.

17 Sep 2012

Alnylam announces complete results from ALN-RSV01 Phase IIb trial on RSV infection

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today complete results from its Phase IIb trial with ALN-RSV01 for the treatment of respiratory syncytial virus (RSV) infection in lung transplant patients.

6 Sep 2012

Enrollment complete in Arrowhead’s CALAA-01 phase 1b trial on solid tumors

Arrowhead Research Corporation, a targeted therapeutics company, today announced that, through its Calando Pharmaceuticals subsidiary, it has completed enrollment of a phase 1b clinical trial of CALAA-01, its RNAi therapeutic candidate targeting solid tumors. All patients participating in the trial have completed dosing with the exception of one patient who is still receiving treatment and will continue to be monitored.

31 Aug 2012

New results describe development of DC cancer vaccine with enhanced immunogenic potential

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, and collaborators at Radboud University Nijmegen Medical Centre in the Netherlands announced today that they have published new pre-clinical results in the journal Cancer Immunology Immunotherapy describing the development of a dendritic cell (DC) cancer vaccine with enhanced immunogenic potential.

23 Aug 2012

Progress with GSK in advancing VaxiRNA technology earns Alnylam $3.2M milestone payment

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has earned a development milestone payment from GlaxoSmithKline, totaling $3.2 million. The milestone payment is related to progress in the companies' collaboration on the use of VaxiRNA technology for the production of GSK influenza vaccine.

30 Jul 2012

Positive results from Alnylam’s ALN-TTR02 Phase I trial on TTR-mediated amyloidosis

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today the achievement of positive clinical results from its Phase I trial with ALN-TTR02, an RNAi therapeutic targeting the transthyretin (TTR) gene for the treatment of TTR-mediated amyloidosis.

16 Jul 2012

New paper documents discovery of novel lipids, including MC3

Alnylam Pharmaceuticals, a leading RNAi therapeutics company, and collaborators announced today the publication of a scientific paper documenting the discovery of novel lipids used in second generation lipid nanoparticles (LNPs) for systemic delivery of RNAi therapeutics.

14 Jul 2012

Oligodendroglia cells: An interview with Jeffrey Rothstein

There are three principle cells in the brain: neurons and two types of glial cells. One type is called an astrocyte. These were well known to inactivate neurotransmitters like glutamate, and provide metabolic support to neurons.

11 Jul 2012

Research into “insulating” brain cells could help to cure neurodegenerative diseases such as ALS

Johns Hopkins researchers say they have discovered that the central nervous system's oligodendroglia cells, long believed to simply insulate nerves as they "fire" signals, are unexpectedly also vital to the survival of neurons. Damage to these insulators appears to contribute to brain injury in neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease for the Yankee baseball great who died from the disease.

11 Jul 2012

Arrowhead initiates Adipotide Phase 1 trial in obesity

Arrowhead Research Corporation, a targeted therapeutics company, today announced that the first patient has been dosed in a Phase 1 clinical trial with Adipotide, a new class of treatment for obesity.

11 Jul 2012

DRCRF names 21 new Damon Runyon Fellows

The Damon Runyon Cancer Research Foundation, a non-profit organization focused on supporting innovative early career researchers, named 21 new Damon Runyon Fellows at its spring Fellowship Award Committee review.

11 Jul 2012

FDA provides Orphan Drug Designation to Alnylam’s ALN-TTR02

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that the U.S. Food & Drug Administration (FDA) has provided Orphan Drug Designation to ALN-TTR02 as a therapeutic for the treatment of familial amyloidotic polyneuropathy (FAP), one of the predominant clinical manifestations of transthyretin (TTR)-mediated amyloidosis (ATTR).

20 Jun 2012

Gene Silencing News and Research

U.S. District Court rules in favor of Alnylam in patent infringement case against Tekmira

LIFR protein suppresses local invasion and metastasis of breast cancer cells

Small fragments of keratin protein in the eye play a key role in warding off pathogens

New light-based technique demonstrates that toxic proteins build up gradually in blood cells

Researchers obtain first detailed and complete picture of PRC2 protein

Single HPV protein is required for cervical cancer growths to survive

Alnylam announces complete results from ALN-RSV01 Phase IIb trial on RSV infection

Enrollment complete in Arrowhead’s CALAA-01 phase 1b trial on solid tumors

New results describe development of DC cancer vaccine with enhanced immunogenic potential

Progress with GSK in advancing VaxiRNA technology earns Alnylam $3.2M milestone payment

Positive results from Alnylam’s ALN-TTR02 Phase I trial on TTR-mediated amyloidosis

New paper documents discovery of novel lipids, including MC3

Oligodendroglia cells: An interview with Jeffrey Rothstein

Research into “insulating” brain cells could help to cure neurodegenerative diseases such as ALS

Arrowhead initiates Adipotide Phase 1 trial in obesity

DRCRF names 21 new Damon Runyon Fellows

FDA provides Orphan Drug Designation to Alnylam’s ALN-TTR02

Arrowhead initiates final IND-enabling steps for ARC-520 to treat HBV

Alnylam announces results from ALN-VSP Phase I study on liver cancers

Top-line results from Alnylam’s ALN-RSV01 Phase IIb trial on RSV infection

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News